IP Library Patent Application 14649651
Patent Application
App. No. 14/649,651

METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/649,651
Abstract

Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.

Claims (18)

1 . A method of treating diabetes in a mammalian subject which comprises administering to said mammalian subject:

(a) a glucagon receptor antagonist, and

(b) a cholesterol absorption inhibitor;

wherein the mammalian subject has an LDL cholesterol plasma level of less than 130 mg/dL.

2 . A method of reducing hyperglycemia in a mammalian subject which comprises administering to said mammalian subject:

(a) a glucagon receptor antagonist, and

(b) a cholesterol absorption inhibitor;

wherein the mammalian subject has an LDL cholesterol plasma level of less than 130 mg/dL.

3 . The method of claim 1 wherein the subject has an LDL cholesterol plasma level of less than 100 mg/dL.

4 . The method of claim 1 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are present in a single dosage form.

5 . The method of claim 4 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are in a bilayer tablet.

6 . The method of claim 1 wherein the glucagon receptor antagonist compound and the cholesterol absorption inhibitor compound are present each in a separate dosage form for simultaneous or sequential administration.

7 . The method of claim 1 for treating type 2 diabetes.

8 . The method of claim 1 the cholesterol absorption inhibitor compound is:

or a pharmaceutically acceptable salt thereof.

9 . The method of claim 1 wherein the glucagon receptor antagonist compound is a compound selected from the following table of compounds:

or a pharmaceutically acceptable salt thereof.

10 - 11 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: DAVIS, HARRY R., JR.; LIN, SONGNIAN; XIONG, YUSHENG; GUAN, HONG-PING; CASTRO-PEREZ, JOSE; JOHNS, DOUGLAS G.; PREVIS, STEPHEN F.; RODDY, THOMAS P.; WANG, LIANGSU; WANG, SHENG-PING; ENGEL, SAMUEL S.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036309/0160 →